Patents by Inventor Delphine Francoise Monique Launay

Delphine Francoise Monique Launay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxaborole analogs and uses thereof
    Patent number: 11691992
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • NOVEL OXABOROLE ANALOGS AND USES THEREOF
    Publication number: 20210253605
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 19, 2021
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Oxaborole analogs and uses thereof
    Patent number: 10961261
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 30, 2021
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretaryof the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • NOVEL OXABOROLE ANALOGS AND USES THEREOF
    Publication number: 20200024289
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 23, 2020
    Applicants: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army, The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE
    Publication number: 20100010057
    Abstract: Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is —(C?O), an optionally substituted divalent phenylene, pyridinylene, pyrimidinylene, or pyrazinylene radical, or a bond; P is optionally substituted C1-C6 alkyl and Z is —(CH2)Z—X1-L1-NHCHR1R2; or Z is optionally substituted C1-C6 alkyl and P is —(CH2)Z—X1-L1-NHCHR1R2; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; X1 is (i) a bond; —NR4C(?O)NR5— or —NR4S(?O)2—; or except when X is —(C?O)— (ii) —C(?O)—, —S(?O)2—, or —S(?O)2NR4— wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; and z and L1 are as defined in the specification.
    Type: Application
    Filed: May 3, 2007
    Publication date: January 14, 2010
    Applicant: CHROMA THERAPEUTICS LTD.
    Inventors: David Charles Festus Moffat, Stephen Davies, Sonia Maria Alesso, Delphine Francoise Monique Launay